SAN FRANCISCO, Dec. 5, 2013 /PRNewswire/ -- Aspira Scientific, Inc., a research and development solutions provider for the chemical and biological sectors, today announces the official launch of its recombinant Human Serum Albumin (rHSA) product. Aspira Scientific's highly pure, cost-effective rHSA is produced from a proprietary expression technology platform, originating from rice grains (Oryza sativa) and is more than 99 percent devoid of any animal, human, or micro-organism derived components ("xeno-free"). To learn more about rHSA, visit www.aspirasci.com/rhsa.
Produced by the innovative plant-based protein technology pioneered by Dr. Daichang Yang of Healthgen Biotechnology Co., Ltd., rHSA has the same application fields as plasma-derived Human Serum Albumin (pHSA), but offers a higher purity, more consistent, xeno-free replacement that can be manufactured to scale. Aspira Scientific's rHSA is made more cost-effectively and safely than other rHSA products, avoiding immunogenicity concerns of rHSA produced in yeast-based expression systems.
"We are proud to collaborate with our strategic manufacturing partner, Healthgen Biotechnology, to offer this ultra-pure, yet highly affordable rHSA for the research market," said Dr. John Chan, CEO, Aspira Scientific. "Our rHSA will fuel innovations in quality-demanding applications such as stem cell therapy, targeted drug delivery, and medical device coating; as well as decrease costs dramatically in high-volume applications such as cell culture media development."
Aspira Scientific's rHSA is manufactured in an ISO 9001 certified facility with rigorous quality control and superior batch-to-batch consistency. The product complies with global regulatory recommendations for non-animal derived components for pharmaceutical related research and development and is available in small-to-large scale commercial quantities.
About Aspira Scientific
Aspira Scientific empowers scientists to achieve their aspirations in chemical and biological research and development by reducing the costs of basic and applied research. The company leverages a global innovation ecosystem to offer a wide array of next-generation enabling research tools. For organizations with developmental programs and commercial intent, Aspira Scientific provides user-driven services via a "Collaborate Locally. Commercialize Globally."™ model to afford exceptional value in terms of innovation, quality and IP assurance, and cost efficiency. For more information, visit www.aspirasci.com.
|SOURCE Aspira Scientific, Inc.|
Copyright©2012 PR Newswire.
All rights reserved